<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004767</url>
  </required_header>
  <id_info>
    <org_study_id>ATRI-004</org_study_id>
    <secondary_id>R01AG053798</secondary_id>
    <nct_id>NCT04004767</nct_id>
  </id_info>
  <brief_title>TRC-PAD Program: In-Clinic Trial-Ready Cohort</brief_title>
  <acronym>TRC-PAD</acronym>
  <official_title>Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Clinical Trials Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cleveland Clinic Lou Ruvo Center for Brain Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the TRC-PAD study is to develop a large, well-characterized,
      biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention
      trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and
      biomarker confirmation. Participants with known biomarker status may have direct referral to
      the Trial-Ready Cohort.

      If you are interested in being selected for the TRC-PAD study, you should first enroll in the
      APT Webstudy (https://www.aptwebstudy.org/welcome).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRC-PAD study is short for the &quot;Trial-Ready Cohort for the Prevention of Alzheimer's
      Dementia&quot;. The purpose of the TRC-PAD study is to find many people (also called a &quot;cohort&quot;)
      who are interested in participating in clinical trials aimed at discovering treatments that
      will reduce the risk of developing Alzheimer's dementia. TRC-PAD will help researchers enroll
      participants into these trials quickly to allow new treatments to be discovered as soon as
      possible.

      The TRC-PAD study is for individuals, age 50 and older, who may be at increased risk for
      memory loss caused by Alzheimer's disease. To join the TRC-PAD study, you first need to be
      invited to complete an in-person TRC-PAD visit.

      How can I be invited to an in-person visit for TRC-PAD? Members of the Alzheimer Prevention
      Trials (APT) Webstudy complete online questionnaires and memory tests. The results of these
      tests will identify individuals as being eligible for an in-person TRC-PAD visit. If you are
      not enrolled in the APT Webstudy, you may be invited to an in-person visit for TRC-PAD
      because other tests or procedures you have had suggest you might be eligible to participate.

      How might the TRC-PAD Study help researchers learn more about Alzheimer's disease dementia?
      Alzheimer's disease remains one of the most important medical conditions for which there is
      no treatment. Among the top ten causes of death, Alzheimer's disease is the only one that
      cannot be prevented, cured, or even slowed. To change this, researchers are conducting
      clinical trials to find new treatments. These trials need to study large numbers of
      individuals and follow participants over long periods of time. The goal of TRC-PAD is to
      identify individuals for these trials. TRC-PAD will find a group of people who may be
      &quot;at-risk&quot; for developing Alzheimer's dementia in the future and are appropriate for
      prevention trials.

      How does TRC-PAD decide that I may have an increased risk for developing Alzheimer's
      dementia? A person's risk for developing Alzheimer's dementia is determined by a number of
      factors including family history, performance on memory tests, and biological tests called
      biomarkers. Biomarkers are measurements in parts of the body - like blood tests or brain
      scans - to help assess the presence of, or potential to develop, a disease.

      If I decide to join TRC-PAD, what happens? Individuals in the TRC-PAD study will complete
      several assessments to see if they qualify to join the cohort. This will include biomarker
      testing (via Positron Emission Tomography (PET) brain scan or spinal fluid collection), tests
      of memory and thinking, questionnaires about daily functioning, mood and behavior, genetic
      testing and routine blood and urine tests. Individuals who are determined to eligible to
      enroll in TRC will come back to the clinic every 6 months for brief longitudinal follow-up
      visits with questionnaires and testing until that individual qualifies for a clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enrollment into preclinical and prodromal AD clinical trials</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimization of adaptive risk algorithm to predict risk of amyloid positivity</measure>
    <time_frame>5 years</time_frame>
    <description>The TRC-PAD program aims to optimize an innovative, adaptive risk algorithm to efficiently identify the most appropriate trial participants. Once optimized, this algorithm will be able to select amyloid positive individuals (and eventually tau and other neurodegenerative biomarkers) with &gt;75% accuracy, greatly reducing future costly biomarker screen fails.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Preclinical Alzheimer's Disease</condition>
  <condition>Prodromal Alzheimer's Disease</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>TRC-PAD Cohort</arm_group_label>
    <description>Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine, CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AD biomarker confirmed individuals who may be at an increased risk for memory loss caused
        by Alzheimer's disease dementia. Individuals at highest risk within the APT Webstudy will
        be referred for an in-person TRC-PAD visit. Individuals with known biomarker status may
        qualify for a direct referral to the trial-ready cohort.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated availability and willingness to comply with all study procedures until referred
             to a clinical trial

          3. Age 50-85 (inclusive)

          4. Global Clinical Dementia Rating (CDR) score of 0 or 0.5 and no diagnosis of dementia

          5. Has a study partner that is willing to participate as a source of information and has
             at least weekly contact with the participant (contact can be in-person, via telephone
             or electronic communication). The study partner must have sufficient contact such that
             the investigator feels the study partner can provide meaningful information about the
             participant's daily function.

          6. In good general health as evidenced by medical history

          7. Adequate visual and auditory acuity to allow neuropsychological testing

          8. Fluent in English or Spanish

          9. For females who are not surgically sterile or post-menopausal by two years, receiving
             a Positron Emission Tomography (PET) scan for amyloid biomarker confirmation: negative
             pregnancy test prior to amyloid PET scan

         10. Completed six grades of education or has a good work history

         11. Evidence of elevated or intermediate (subthreshold) levels brain amyloid as assessed
             by central review of amyloid PET or cerebrospinal fluid (CSF) data. Prior amyloid
             testing results may be used with approval from the Coordinating Center.

        Exclusion Criteria:

          1. Treatment with another anti-amyloid investigational drug or other intervention within
             12 months

          2. Enrolled in another interventional clinical trial within the last 12 weeks

          3. Any significant neurologic disease such as Alzheimer's disease dementia, Parkinson's
             disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus,
             brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma,
             multiple sclerosis, or history of significant head trauma followed by persistent
             neurologic deficits or known structural brain abnormalities.

          4. Major depression, bipolar disorder as described in DSM-V within the past 1 year or
             psychotic features, agitation or behavioral problems within 3 months, which could lead
             to difficulty complying with the protocol

          5. History of schizophrenia (DSM V criteria)

          6. History of alcohol or substance abuse or dependence within the past 2 years (DSM V
             criteria)

          7. Clinically significant or unstable medical condition, including uncontrolled
             hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal,
             hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may
             either put the participant at risk because of participation in the study, or influence
             the results, or the participant's ability to participate in the study.

          8. History within the last 3 years of a primary or recurrent malignant disease with the
             exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in
             situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer
             with normal prostate-specific antigen post-treatment

          9. Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that
             might interfere with the study. A low B12 is exclusionary, unless follow-up labs
             (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not
             physiologically significant.

         10. Clinically significant abnormalities in screening laboratories or ECG.

         11. For participants undergoing CSF collection: a current blood clotting or bleeding
             disorder, or significantly abnormal PT or PTT at screening or if on anti-coagulation
             (e.g. warfarin)

         12. Participants whom the Site PI deems to be otherwise ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Aisen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reisa Sperling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Lou Ruvo Center for Brain Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>APT / TRC Recruitment Team</last_name>
    <phone>858-877-3135</phone>
    <email>info@aptwebstudy.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Geldmacher, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Tauchmann</last_name>
      <phone>602-839-4891</phone>
      <email>Daniela.Tauchmann@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>David Weidman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadira Trncic</last_name>
      <phone>623-832-6590</phone>
      <email>Nadira.Trncic@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Alireza Atri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Vides</last_name>
      <phone>949-824-3250</phone>
      <email>byanez@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Grill, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Becerra</last_name>
      <phone>329-442-7594</phone>
      <email>Mauricio.Becerra@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lyn Than</last_name>
      <phone>329-442-7603</phone>
      <email>Lyn.Than@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lon Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adam Boxer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>945985900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Olichney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher H van Dyck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>200072145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly McCann</last_name>
      <phone>202-687-0413</phone>
      <email>keb53@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond Scott Turner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neill Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wien Center for Alzheimer's Disease</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie A Rodriguez</last_name>
      <phone>305-674-2121</phone>
      <phone_ext>56771</phone_ext>
      <email>Rosemarie.Rodriguez@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Ranjan Duara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-381-9060</phone>
      <email>jlesmes@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Yolanda Gonzalez</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>1141</phone_ext>
      <email>ygonzalez@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Brody, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Health Byrd Alzheimer Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>336134808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juris Janavs</last_name>
      <phone>813-396-0637</phone>
      <email>jjanavs@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phyllis L Vaughn</last_name>
      <phone>404-712-6901</phone>
      <email>pvaughn@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Allan I Levey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Liambotis</last_name>
      <phone>312-563-0523</phone>
      <email>Peter_J_Liambotis@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Neelum Aggarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kala Hall</last_name>
      <phone>317-963-1867</phone>
      <email>kalhall@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Farlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Brook</last_name>
      <phone>901-866-9252</phone>
      <email>dbrook@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Townley, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>405042681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hope Esposito</last_name>
      <phone>859-323-4547</phone>
      <email>hope.esposito@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Jicha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212242764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Horn</last_name>
      <phone>410-550-9020</phone>
      <email>shorn8@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21155804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Kuney</last_name>
      <phone>617-732-7992</phone>
      <email>skuney@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Gad Marshall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Mackenzie</last_name>
      <phone>734-232-2415</phone>
      <email>spearsl@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Judith Heidebrink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Etbauer</last_name>
      <phone>507-284-1324</phone>
      <email>etbauer.kimberly@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Graff-Radford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>631082215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Santos</last_name>
      <phone>314-286-2363</phone>
      <email>mhsantos@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Joy Snyder, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>891060100</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grey Rivera</last_name>
      <email>riverag@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Marwan Sabbagh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esmeralda Morales</last_name>
      <phone>585-760-6562</phone>
      <email>esmeraldamorales@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abigail O'Connell</last_name>
      <phone>336-716-7976</phone>
      <email>abigail.oconnell@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Suzanne Craft, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>441224312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Posan</last_name>
      <email>Megan.Posan2@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Rajeet Shrestha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>972393011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Spoden</last_name>
      <phone>503-494-0976</phone>
      <email>spoden@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Aimee Pierce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Weiss</last_name>
      <phone>215-615-3133</phone>
      <email>allison.weiss@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjeev Vaishnavi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinneil Simmons</last_name>
      <phone>401-444-2421</phone>
      <email>quinneil.simmons@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Brian Ott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital Memory and Aging Program</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Daneault</last_name>
      <phone>860-908-6738</phone>
      <email>KDaneault@buttler.org</email>
    </contact>
    <investigator>
      <last_name>Athene Lee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Lapp</last_name>
      <phone>843-724-2214</phone>
      <email>allison.lapp@rsfh.com</email>
    </contact>
    <investigator>
      <last_name>Jacobo Mintzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Brendan Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Sciences Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leigh Johnson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington / Seattle Institute for Biomedical and Clinical Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elaine Peskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.aptwebstudy.org/welcome</url>
    <description>APT Webstudy</description>
  </link>
  <link>
    <url>https://keck.usc.edu/atri/research/studies/</url>
    <description>ATRI Studies</description>
  </link>
  <link>
    <url>https://www.actcinfo.org/</url>
    <description>Alzheimer's Clinical Trials Consortium</description>
  </link>
  <reference>
    <citation>Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA; Alzheimer’s Disease Cooperative Study. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015 Apr;72(4):446-54. doi: 10.1001/jamaneurol.2014.3375. Erratum in: JAMA Neurol. 2015 May;72(5):608.</citation>
    <PMID>25706191</PMID>
  </reference>
  <reference>
    <citation>Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.</citation>
    <PMID>28253478</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Paul Aisen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Prevention</keyword>
  <keyword>Observational</keyword>
  <keyword>Trial-Ready Cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

